The Venture Codex

Participated · Series C · Apr 2025

Biolinq is a healthcare technology company developing precision intradermal biosensors to improve metabolic health. Its initial product is a wearable biosensor patch with an array of tiny electrochemical microsensors that measure glucose continuously just beneath the skin’s surface, providing real-time feedback via a color-changing indicator light on the upper forearm. The device is designed to combine glucose monitoring with activity and sleep information to support people with Type 2 diabetes not on insulin. Biolinq’s platform is positioned for future multi-analyte sensing capabilities and the company says it has spent the last decade developing the underlying technology. The company recently completed a US pivotal trial and submitted for regulatory review; its intradermal glucose sensor remains investigational and is not yet FDA cleared. A $100 million Series C will finance the company’s push from development toward commercial readiness as it pursues US regulatory approval; Biolinq is headquartered in San Diego. Biolinq develops a wearable patch that uses an array of tiny electrochemical microsensors placed in the intradermal space to measure glucose and relative activity from just beneath the skin surface. The device is designed for simplicity and user feedback, with an intuitive on-device display that notifies users when glucose is within or outside target ranges. Its sensor array is engineered for redundancy, reliability and multi-analyte capabilities without the use of introducer needles or bleeding. Biolinq describes the intradermal glucose sensor as investigational and not yet cleared or approved by the FDA. The company is headquartered in San Diego, CA. Proceeds from the completed financing will fund completion of a U.S. pivotal clinical trial this year and support a subsequent FDA submission. Biolinq is developing a wearable biosensor platform whose first product is a needle-free, intelligent continuous glucose sensor with a novel integrated display on the device. The device leverages semiconductor-industry innovation to miniaturize electrochemical sensors into a micro-array of miniature biosensors roughly 25 times smaller than conventional glucose sensors, enabling redundant measurements for reliability. Early feasibility studies demonstrated the microarray patch can track glucose continuously for up to seven days in people with diabetes. Biolinq’s approach includes multiplexed sensing capabilities and immediate biosensor feedback designed to simplify diabetes management and support future consumer health and wellness applications. The company is advancing clinical, regulatory, manufacturing and commercialization milestones to expand the sensing category. Financially, Biolinq completed a $100 million Series B financing, described as a record private capital raise in the continuous glucose monitoring space, with a broad syndicate of strategic and financial investors. Biolinq is developing a skin-applied, minimally-invasive electrochemical biosensor platform that analyzes interstitial fluid to provide actionable health information. Its first commercial product aims to let people with diabetes continuously monitor blood glucose without the pain and hassle of traditional continuous glucose monitoring systems. The platform is wirelessly enabled and designed to simultaneously measure multiple biomarkers, enabling a pipeline of biomonitoring products. Biolinq plans to use new financing to support growth of its technology platform and to fund additional clinical studies. The company completed its first clinical study in 2018 and reports promising initial clinical results. Biolinq was founded in 2012 and is located in San Diego. Biolinq develops a skin-applied, minimally-invasive electrochemical biosensor platform that analyzes biomarkers in interstitial fluid. Its wirelessly-enabled, nickel-sized biosensor patch is designed to continuously monitor multiple biomarkers and its first commercial product targets blood glucose monitoring without the pain and hassle of traditional CGM systems. The company emphasizes factory calibration (no finger sticks), low cost-of-goods, high manufacturing uniformity, and ease of use. Biolinq intends to leverage its novel manufacturing approach to increase access to CGM and simplify diabetes management. The platform’s ability to simultaneously measure multiple biomarkers supports plans to build a pipeline of additional biomonitoring products. Biolinq was founded in 2012 (as Electrozyme, LLC) and is located in San Diego.

Participated · Series A · Mar 2024

VIE (formerly VIE STYLE) builds earbud-type EEG devices that use the eartip as an electrode to collect brainwaves with the simplicity of standard earphones. Its flagship hardware includes VIE ZONE, an earphone-form wearable EEG, and VIE CHILL, a high-performance wireless earphone that analyzes users' brainwaves and generates music to guide ideal brain states. The company also offers a brainwave-music app, VIE Tunes, which reached 40,000 downloads within three months of launch. VIE is pursuing both consumer expansion and applied use in medical, healthcare, and sensing contexts, and is developing industry-specific products through partnerships. The firm says it will continue investing in research and business development to accelerate technology and hardware work and to address social challenges. Current product strategy blends hardware, neurofeedback software, and generated "neuromusic" to create measurable wellbeing experiences.

Participated · Series A · Jul 2023

Toregem BioPharma is developing TRG-035, an experimental antibody therapy designed to neutralize USAG-1, a protein that suppresses tooth formation, with the goal of reactivating dormant tooth buds and prompting natural tooth development. The company’s initial clinical focus is on patients with congenital tooth agenesis, with broader potential envisioned for stimulating a “third dentition” to treat tooth loss from aging, decay, or injury. Preclinical evidence of tooth regeneration has come primarily from animal studies (mice), while human testing to date has focused on safety. Toregem launched a Phase I trial at Kyoto University Hospital in October 2024 that enrolled 30 healthy adult men missing at least one molar; recruitment was reported to have stopped by March 2026 and the study is operationally complete, though full results have not been published. Toregem has secured a mix of equity financing and non-dilutive support (grants and subsidies) and reports cumulative funding above $29 million. The company is using its recent Pre-Series C proceeds to advance Phase II trials in Japan and to prepare for clinical development in the United States.

Participated · Equity · Apr 2021

Edifice Health applies novel proteomic approaches combined with proprietary artificial intelligence and predictive analysis to measure the rate at which an individual’s body ages. The company created a metric to measure systemic chronic inflammation, which Stanford Project research identified as a root cause and predictor of multiple chronic diseases of aging. Edifice has identified interventional supplements that can be targeted to an individual’s immunotype to improve inflammatory health and support healthy aging. The company was born out of the Stanford 1,000 Immunomes Project following NIH-funded research in immunological health and aging at Stanford University. Led by Chairman and CEO Wolfgang Daum, PhD, with founder David Furman, PhD active on the board, Edifice is building its scientific foundation and product capabilities. The company intends to use the new funding to grow its immunological science and add additional talent.